08:58 AM EDT, 09/26/2024 (MT Newswires) -- Acumen Pharmaceuticals ( ABOS ) said Thursday that it has extended its partnership with Lonza to offer drug product manufacturing for clinical and potential commercial supply from the latter's Visp, Switzerland, facility to treat Alzheimer's disease.

The extended agreement requires Lonza to produce cGMP drug product of sabirnetug for the current and future clinical studies and also provide quality control and stability testing, Acumen said.

Financial details of the partnership were not disclosed.

The companies first signed a collaboration deal in April.

Shares of the company were up 5% in recent Thursday premarket activity.

Price: 2.4600, Change: +0.12, Percent Change: +5.13